ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 1130

Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI

(1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1374

Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival

(1365–1382) Sjögren’s Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1528

Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients

(1513–1533) Systemic Sclerosis & Related Disorders – Clinical Poster II: Clinical Trial, Treatment & Intervention

9:00AM-11:00AM: Abstract Number: 1502

Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study

(1488–1512) SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0875

INV-1498, a Promising Caspase Inhibitor, Exhibits Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis

(0859–0885) Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1208

Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study

(1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 0919

Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0893

Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model

(0886–0898) SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1431

Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results

(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

9:00AM-11:00AM: Abstract Number: 0950

KL-6 and IL-18 Levels Are Negatively Correlated with Respiratory Function Tests and ILD Extent Assessed on HRCT in Patients with Systemic Sclerosis-related Interstitial Lung Disease (SSc-ILD)

(0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 0904

KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1538

Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades

(1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

9:00AM-11:00AM: Abstract Number: 1012

Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial

(0993–1012) Health Services Research Poster II

9:00AM-11:00AM: Abstract Number: 0895

Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus

(0886–0898) SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1250

Local Inflammatory Response Mediated by the Homing of Tfh17 Cells Is Involved in Tissue Injury of Immunoglobulin a Vasculitis

(1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].